Clinically, EZH2 expression in the invasive edge correlates with radiotherapy resistance: a retrospective study of 57 GBM patients found that high EZH2 levels in pre-radiotherapy invasive edges predicted a 2.4-fold higher recurrence rate and 35% shorter progression-free survival (Kim et al., 2024). The gene discussed is EZH2; the disease is glioblastoma.